Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will
evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate,
symptomatic, confirmed COVID 19.
Phase:
Phase 2
Details
Lead Sponsor:
DalCor Pharmaceuticals
Collaborators:
Covance The Montreal Health Innovations Coordinating Center (MHICC)